Pharming (PHAR) - Market Capitalization
Pharming Group N.V. (PHAR) specializes in the therapy of rare immune pathologies, utilizing innovative molecule extraction from genetically modified rabbit milk, which renders Ruconest a high-margin product. The price action on this chart, which currently stands at 0.95, links this success to a model of fully delegating production and trials to external partners. Simultaneously, the business minimizes dependency risks associated with CMO plants through long-term agreements and digital logistics.
Comprehensive metric breakdowns and analytics for Pharming Corp (PHAR)
- current price and projected stock value:
- market capitalization indicators:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Pharming Group N.V.|PHAR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Pharming Group N.V.|PHAR - Company Aggregate Debts|Debt to Book Capitalization Ratio Pharming Corp|PHAR - Company Long-Term Loans and Borrowings|Company Short-Term Debt Pharming Group|Quick Ratio pharming.com
- business earnings and investment ratios data:
PHAR - Net Profit|Future Profit Pharming Group N.V.|PHAR - Company Value to Net Income|Forward P/E Multiple Pharming|PHAR - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming Corp|PHAR - Operating profit before deduction of amortization|Earnings per share for the last twelve months Pharming Group|PHAR - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months pharming.com|PHAR - Earnings growth in current year|Net earnings per share growth forecast for next year Pharming Group N.V.
Fundamental company analysis:PHAR (Pharming Group)
Market capitalization aggregates current asset demand, reflecting the total value of all issued shares through the lens of market expectations. The market value dynamics of all Pharming Group N.V. (PHAR) shares allow for an assessment of the premium investors are willing to pay for ownership of a unique recombinant protein production complex, given the stability of product supplies from high-tech laboratories in the Netherlands.
Key competitors
Market Capitalization ARGX (argenx)|Market Value BNTX|Abivax S.A. - Market Capitalization|ADMA - Market Capitalization|Protagonist Therapeutics (PTGX) - Market Value|immunovant.com - Market Value|Market Value Kiniksa|Grifols SA - Market Valuation|Market Capitalization ADPT|CLDX (Celldex Corp) - Market Value|Market Capitalization AUPH (Aurinia Pharmaceuticals)|Market Capitalization biocryst.com BCRX|VERA - Market Value|Market Value DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp (PHVS) - Market Value|Market Valuation AbCellera Biologics Inc.|TRML (Tourmaline Bio, Inc.) - Market Capitalization|Market Capitalization precigen.com|Market Valuation NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Market Value|Market Capitalization ZBIO (Zenas Biopharma, Inc.)|Market Capitalization Immunome Bio (IMNM)|GOSS - Market Value|kalvista.com (KALV) - Market Valuation|Septerna (SEPN) - Market Value|Market Valuation Pieris Pharma|Market Valuation SVRA|Market Capitalization Rigel Corp|Market Value AnaptysBio, Inc. (ANAB)|astriatx.com - Market Capitalization|Market Capitalization ENGN (enGene)|rapt.com (RAPT) - Market Value|JBIO - Market Value|Market Valuation ACRS|KYTX: Market Capitalization|tizianalifesciences.com - Market Value|CABA (Cabaletta Bio) - Market Capitalization|Market Capitalization Ventyx Biosciences Inc.|Market Value Theratechnologies Inc (THTX)|AVTX (Avalo Therapeutics Inc) - Market Value|Market Value Eledon Pharmaceuticals ELDN|AGEN - Market Valuation|Climb Bio - Market Capitalization|Market Capitalization zurabio.com ZURA|aTyr (ATYR) - Market Value|Market Capitalization ADAG|IMA (ImageneBio) - Market Capitalization|STTK - Market Capitalization|Market Valuation EQ (Equillium, Inc.)|CNTB (connectbiopharm.com) - Market Value|Market Capitalization IMUX (Immunic)|Market Capitalization Atara Biotherapeutics, Inc.|IFRX - Market Value|Market Value XFOR (x4pharma.com)|adicetbio.com (ACET) - Market Value|Market Value Celularity (CELU)|Market Valuation INMB|Market Capitalization Barinthus Biotherapeutics Corp|Market Value Kezar Life Sciences (KZR)|SABS: Market Valuation|Akari Therapeutics Plc - Market Valuation|Market Value ENLV|QTTB - Market Value|GOVX (GeoVax Corp) - Market Capitalization|EDSA (Edesa Biotech, Inc.) - Market Valuation|IBIO - Market Capitalization|Market Valuation CARM|Market Value XTLB|Market Valuation BOLT (Bolt Biotherapeutics)|Market Capitalization hcwbiologics.com|Market Value Aptevo Therapeutics Inc. APVO|AIM (aimimmuno.com) - Market Valuation|Aditxt Corp - Market Capitalization|Market Value GRI (GRI Bio Inc)|XRTX: Market Capitalization|Vyome Therapeutics (HIND) - Market Capitalization|Market Value Revelation Biosciences|INDP: Market Value|Market Value Scinai Immunotherapeutics Ltd. (SCNI)|CALI: Market Valuation|Market Capitalization AFMD (Affimed N.V.)|Market Value ALLK|HOOKIPA - Market Capitalization|IGMS - Market Capitalization|iTeos Therapeutics, Inc. (ITOS) - Market Value|Ocean Biomedical Inc - Market Value|Market Value TC BioPharm (Holdings) PLC|Market Valuation Third Harmonic Bio Inc (THRD)
